Compare IDEXX Laboratories, Inc. (IDXX) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs MasTec Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while MasTec Inc trades at $280.16 (market cap $21.90B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.1× MasTec Inc's market cap, and MasTec Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | MTZ | |
|---|---|---|
Market Cap | $46.22B | $21.90B |
Sector | Health | Technology |
52-Week High | $766.68 | $437.51 |
52-Week Low | $526.44 | $172.51 |
Enterprise Value | $47.12B | $24.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
MasTec (MTZ) trades at $281.11, up 4.78% over 24 hours, amid strong 2026 performance with record Q2 revenue of $4.37 billion and a $21.4 billion backlog. Technical indicators show a bearish trend with resistance near $283, while fundamentals reflect robust growth—40% EBITDA growth in Q2—though valuation multiples like a P/E of 43.42 suggest premium pricing. Recent news highlights the acquisition of The Superior Group and a $650 million senior notes offering, bolstering infrastructure capabilities.
The outlook is positive, driven by infrastructure demand and raised 2026 guidance, but risks include execution challenges from acquisitions and communications segment delays. Analysts are overwhelmingly bullish with an 88.89% buy rating and a $439.56 consensus target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
